Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

In the News
Greg Scott presents industry update during JPMorgan
>> View video…

>> More News...

Now on Twitter!
 

Twitter ID: ChinaBio

SL Pharma Wins SFDA Approval for New Drug and a Clinical Trial

publication date: Aug 28, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Beijing SL Pharmaceutical Co. Ltd. received SFDA approval to begin producing a hepatitis drug and a second SFDA authorization to begin clinical trials of drug for male infertility. Adefovir dipivoxil, the drug newly approved for marketing, is aimed at hepatitis B. SL Pharma’s male infertility product is thought to be modafinil, the stimulant drug that is marketed as Provigil by Cephalon. More details...

Stock Symbols: (SZSE: 002038) (NSDQ: CEPH)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
ChinaBio® Events
April 14, 2010
Guangzhou, China

SEED Final Competion and Award Ceremony
April 23, 2010
Shanghai, China
Suzhou, China
June 23-24, 2010
 
Partner Events

China 2010 Pharmaceutical R&D Summit
Shanghai, China
April 5-8, 2010

Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners